GlaxoSmithKline Plc: The Cheap Remedy For Market Upsets

GlaxoSmithKline plc (LON:GSK) is a quality defensive share at a reasonable price.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Recent turbulence in the markets is a reminder of the benefits of having a core holding of defensive shares. But dire interest rates and fear of a bond bear market have spurred investors to switch from cash and bonds into quality defensive shares, many of which pay handsome yields and offer bond-like security.

The result? Stocks like Unilever and Diageo are trading at historically high multiples, with prospective price-to-earnings (P/E) multiples of 19.7 and 19.4 respectively. It’s no cause to panic — both these stocks have great brands and diversified earnings. Investors may sacrifice potential upside if there’s a stock market rally but they’re getting good downside protection in return, while picking up a decent yield.


But for my money, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) stands out as the cheapest of the quality defensive stocks. It’s on a prospective P/E of 15, not far above the market average, and yields 4.5%.

I’m not alone in being a fan of GSK. Deutsche Bank upgraded the shares to a ‘buy’ last month and said they should trade at 1,930p to be on a par with peers whose shares have recovered better since earnings were downgraded in the sector in 2011. That helped push GSK’s shares to an 11-year high, but at 1,742p today they’re still well below Deutsche’s target price.

Barclays upgraded GSK in January. The indication from both brokers is that the company has turned the corner on its patent cliff, the issue that has dogged pharmaceutical companies in recent years. The impact of drugs coming off patent has mostly run its course with GSK and new products are in the offing, including melanoma, HIV and lung disease therapies.


What’s more, GSK successfully diversified away from a pure pharma business model some years ago. 30% of sales come from vaccines, which have a lower-risk profile, and consumer healthcare, with products such as Lucozade, Sensodyne and Panadol.

It has also pushed hard into emerging markets where growing and ageing middle classes are driving increased drugs sales, though recent developments in China highlight the dangers inherent in such countries. China’s anti-trust watchdog is expected to force down prices, while some GSK employees have been accused of ‘economic crimes’.

GSK has another fan, too. One of its biggest shareholders is Invesco Perpetual’s star fund manager Neil Woodford. Mr Woodford’s high income fund is “the best performing of any fund investing in the UK since it launched”, according to Hargreaves Lansdown. Nearly a quarter of his £22bn funds are invested in just three companies in the pharmaceutical sector, including GSK.

You can learn more about how Mr Woodford selects stocks, and the identity of his other pharmaceutical investments, in an exclusive report from the Motley Fool. You can download it by clicking here — it’s free.

> Tony owns shares in GSK, Unilever and Diageo but no other shares mentioned in this article. The Motley Fool has recommended shares in Unilever.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

Potentially 42% undervalued, is this FTSE 100 company a sleeping giant?

The FTSE 100 is full of opportunities for the patient investor, and I think I may have found one that…

Read more »

Investing Articles

AstraZeneca, a mega-cap growth stock that just got cheaper!

Our writer takes a closer look at this growth stock -- which also happens to be the largest company of…

Read more »

Investing Articles

How I’d invest £5,000 in FTSE growth stocks right now

Sumayya Mansoor explains why she’s bullish about these FTSE growth stocks, and would be willing to buy some shares.

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

ITV shares down after revenue guidance cut in first-half interim results

After releasing results this morning, the ITV share price slumped. But with several metrics looking positive, how will this effect…

Read more »

Investing Articles

This FTSE 100 stock’s down 50%, and a director just bought 8,000 shares

Directors of this blue-chip company have been snapping up a load of its shares. Should I do likewise and buy…

Read more »

Investing Articles

The BT share price is far too cheap, analysts say!

The BT share price fell on Thursday 25 July after the company's Q1 results. Dr James Fox takes a closer…

Read more »

Investing Articles

Is this the start of a stock market crash?

Global stock markets are experiencing some turbulence at the moment. Could investors be looking at a major decline in share…

Read more »

Investing Articles

As the Anglo American share price holds up on H1 results, should I buy?

Failed takeover attempts and major restructuring all affect the Anglo American share price. Here's what's happening at H1 time.

Read more »